- Agreement with speciality chemical company, Croda International, to design and manufacture a new active skincare ingredient based on SkinBiotix™ technology and investigate specific cosmetic ingredient applications to target.
- First commercial deal around SkinBioTherapeutics’ SkinBiotix™ technology.
- Croda is an international speciality chemical company supplying some of the world’s biggest brands.
UK skin health company, SkinBioTherapeutics, has signed a commercial agreement with FTSE 100 company Croda International for the design and manufacture of a new active cosmetic skincare ingredient based on its pioneering SkinBiotix™ skin microbiome technology.
Powered by the discoveries about lysates and the skin microbiome made at the University of Manchester by Professor Cath O’Neill and Professor Andrew McBain, SkinBioTherapeutics is developing a range of scientifically-validated treatments derived from probiotic bacteria. SkinBioTherapeutics’ patented skin microbiome technology, SkinBiotix®, applies lysates derived from probiotic bacteria to the skin, and has been shown to improve the barrier effect of skin models, protect skin models from infection and repair skin models.
Under the terms of the agreement, SkinBioTherapeutics’ proprietary SkinBiotix™ platform will be paired with Croda’s expertise in the development and commercialisation of unique, sustainable, cosmetic ingredients, focusing specifically on the growing skincare actives market. Sederma, part of Croda International, is a specialist in bioactive ingredients for the cosmetic industry, and will be responsible for the development, manufacturing and commercialisation of the SkinBiotix™ technology. As design and build of the active ingredient is carried out there will be concurrent testing in focussed application areas which will be detailed in further, additional agreements.
Any licensed products resulting from this agreement will be sold to Croda’s global portfolio of Personal Care customers. Sales and distribution rights are for the cosmetic sector alone, leaving SkinBioTherapeutics to focus on further applications of its technology in other sectors.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Arnaud Fournial, Managing Director of Sederma, said: “The SkinBiotix™ technology has a solid scientific foundation which attracted us in the first place. We believe the technology has the potential to become an essential and significant component of cosmetic products within the rapidly emerging skin microbiome market. We look forward to a fully collaborative partnership with the SkinBioTherapeutics team and to seeing SkinBiotix™ being embraced by our global partners as a key ingredient across a variety of products to protect and rejuvenate skin.”
Stuart Ashman, CEO of SkinBioTherapeutics, said: “We are delighted to have partnered with a world-leading company such as Croda and to able to utilise the expertise within Sederma. This partnership brings together our innovation in the microbiome space and Sederma’s track record of developing world-class cosmetic ingredients. The strong scientific foundation for our technology, and the pioneering research conducted by our CSO Dr Cath O’Neill to date, has put us in a very strong position to develop a cosmetic ingredient with the potential to really exploit the full potential of the skin microbiome.”
Source: Biospace
